Loading company…
Seoul-based developer of molecular diagnostic tests for stage II-III gastric cancer patients, including the nProfiler 1 assay.
Established in 2010 and based in Seoul, South Korea, Novomics Co., Ltd. develops molecular diagnostic tests for stage II-III gastric cancer patients. Its nProfiler 1 Stomach Cancer Assay gives clinicians prognostic information to help plan treatment and avoid over- or under-treatment. The company passed China Inspection and Quarantine Certification in 2020.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in